Cladribine, cytarabine and idarubicin (CLA-Ida) salvage chemotherapy in relapsed acute myeloid leukemia (AML)

References

• Burnett AK, Russel NH, Hills RK, et al. A randomized comparison of daunorubicin 90 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients. Blood. 2015;125:378–385.
   Web of Science ®Google Scholar
• Wrzesien-Kus A, Robak T, Lech-Maranda E, et al. A multicenter, open, non-comparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, and G-CSF as induction therapy in refractory acute myeloid leukemia – a report of the Polish Adult Leukemia Group (PALG). Eur J Hematol. 2003;71:155–162.
   PubMed Web of Science ®Google Scholar
• Wei A, The TC. Salvaging AML with CLAG: novel option, or more of the same? Leukemia Res. 2011;35:297–298.
   PubMed Web of Science ®Google Scholar
• Shen Y, Chen J, Liu Y, et al. Addition of Cladribine to Idarubicin and Cytarabine during induction increases the overall efficacy rate in adult patients with acute myeloid leukemia: a matched-pair retrospective comparison. Chemotherapy. 2014;60:368–374.
   PubMed Web of Science ®Google Scholar
• Clavio M, Carrara P, Miglino M. High efficacy of fludarabine-containing therapy (FLAG-FLANG) in poor risk acute myeloid leukemia. Haematologica. 1996;81:513–520.
   PubMed Web of Science ®Google Scholar
• Nokes TJC, Johnson S, Harvey D, et al. FLAG is a useful regimen for poor prognosis adult myeloid leukemia and myelodysplastic syndromes. Leuk Lymphoma. 1997;27:93–101.
   PubMed Web of Science ®Google Scholar
• Montillo M, Mirto S, Petti MC. Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia . Am J Hematol. 1998;58:105–109.
   PubMed Web of Science ®Google Scholar
• Jackson G, Taylor P, Smith GM. A multicenter, open, non-comparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukemia and de novo refractory anaemia with excess of blasts in transformation. Br J Hematol. 2001;112:127–137.
   PubMed Web of Science ®Google Scholar
• Carella MA, Cascavilla M, Greco MM, et al. Treatment of “poor risk” acute myeloid leukemia with fludarabine, cytarabine and G-CSF (flag regimen): a single center study . Leuk Lymphoma. 2001;40:295–303.
   PubMed Web of Science ®Google Scholar
• Holowiecki J, Grosicki S, Giebel S, et al. Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study. J Clin Oncol. 2012;30:2441–2448.
   PubMed Web of Science ®Google Scholar
• Juliusson G, Hoglund M, Karlsson K, et al. Leukemia Group of Middle Sweden. Increased remissions from one course for intermediate-dose cytosine arabinoside and idarubicin in elderly acute myeloid leukemia when combined with cladribine. A randomized population-based phase II study. Br J Hematol. 2003;123:810–818.
   PubMed Web of Science ®Google Scholar
• Robak T, Wrzesien-Kus A, Lech-Maranda E, et al. Combination regimen of cladribine, cytarabine and G-CSF (CLAG) as induction therapy for patients with relapsed and refractory acute myeloid leukemia. Leuk Lymphoma. 2000;39:121–129.
   PubMed Web of Science ®Google Scholar
• Freyer CW, Gupta N, Wetzler M, et al. Revisiting the role of cladribine in acute myeloid leukemia: an improvement on past accomplishments or more old news? Am J Hematol. 2015;90:62–72.
   PubMed Web of Science ®Google Scholar
• Holowiecki J, Grosicki S, Robak T, et al. Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, Phase III Study. Leukemia. 2004;18:989–997.
   PubMed Web of Science ®Google Scholar
• Martin MG, Welch JS, Augustin K, et al. Cladribine in the treatment of acute myeloid leukemia: a single-institution experience. Clin Lymphoma Myeloma. 2009;9:298–301.
   PubMedGoogle Scholar
• Price SL, Lancet JE, George TJ, et al. Salvage chemotherapy regimens for acute myeloid leukemia: Is one better? Efficacy comparison between CLAG and MEC regimens. Leukemia Res. 2011;35:301–304.
   PubMed Web of Science ®Google Scholar
• Gandhi V, Estey E, Keating MJ, et al. Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions. Blood. 1996;87:256–264.
   PubMed Web of Science ®Google Scholar
• Robak T. Purine nucleoside analogues in the treatment of myleoid leukemias. Leuk Lymphoma. 2003;44:391–409.
   PubMed Web of Science ®Google Scholar
• Kornblau SM, Gandhi V, Andreeff M, et al. Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults. Leukemia. 1996;10:1563–1569.
   PubMed Web of Science ®Google Scholar
• Robak T, Wierzbowska A. Cladribine in the treatment of acute myeloid leukemia. Leukemia Res. 2014;38:425–427.
   PubMed Web of Science ®Google Scholar
• Jaglal MV, Duong VH, Bello CM, et al. Cladribine, cytarabine, filgrastim, and mitoxantrone (CLAG-M) compared to standard induction in acute myeloid leukemia from myelodysplastic syndrome after azanucleoside failure. Leukemia Res. 2014;38:443–446.
   PubMed Web of Science ®Google Scholar
• Wierzbowska A, Robak T, Pluta A, et al. Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group. Eur J Hematol. 2008;80:115–126.
   PubMed Web of Science ®Google Scholar
• Libura M, Giebel S, Piatowska-Jakubas B, et al. Cladribine added to daunorubicin-cytarabine induction prolongs survival of FLT3-ITD+ normal karyotype AML patients. Blood. 2016;127:360–362.
   PubMed Web of Science ®Google Scholar
• Roboz GJ, Rosenblat T, Arellano M, et al. International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemia. J Clin Oncol. 2014;32:1919–1926.
   PubMed Web of Science ®Google Scholar
• Faderl S, Wetzler M, Rizzieri D, et al. Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I trial. J Clin Oncol. 2012;30:2492–2499.
   PubMed Web of Science ®Google Scholar
• Giles F, Vey N, DeAngelo D. Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapse. Blood. 2009;114:4027–4033.
   PubMed Web of Science ®Google Scholar
• Ravandi F, Ritchie EK, Sayar H, et al. Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study. Lancet Oncol. 2015;16:1025–1036.
   PubMed Web of Science ®Google Scholar
• Chow KU, Boehrer S, Napieralski, et al. In AML cell lines Ara-C combined with purine analogs is able to exert synergistic as well as antagonistic effects on proliferation, apoptosis and disruption of mitochondrial membrane potential. Leuk Lymphoma. 2003;44:165–173.
   PubMed Web of Science ®Google Scholar
• Carson DA, Wasson DB, Taetle R, et al. Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes. Blood. 1983;62:737–743.
   PubMed Web of Science ®Google Scholar
• Genini D, Adachi S, Chao Q, et al. Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria. Blood. 2000;96:3537–3543.
   PubMed Web of Science ®Google Scholar